Legal Representation
Attorney
W. Dennis Drehkoff
USPTO Deadlines
Application History
26 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jun 22, 2009 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
Jun 22, 2009 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
Oct 31, 2008 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
Oct 30, 2008 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
Oct 29, 2008 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Oct 29, 2008 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
May 16, 2008 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
May 16, 2008 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
May 16, 2008 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Nov 20, 2007 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Aug 28, 2007 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Aug 8, 2007 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
Jul 20, 2007 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
Jul 20, 2007 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
Jul 20, 2007 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Jul 20, 2007 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Jul 20, 2007 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Jul 20, 2007 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
Jul 10, 2007 | ALIE | A | ASSIGNED TO LIE | Loading... |
Jul 10, 2007 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Jul 10, 2007 | ACEC | I | AMENDMENT FROM APPLICANT ENTERED | Loading... |
Jun 26, 2007 | I | PAPER RECEIVED | Loading... | |
Apr 26, 2007 | CPRA | R | PRIORITY ACTION WRITTEN | Loading... |
Apr 26, 2007 | GPRA | F | PRIORITY ACTION E-MAILED | Loading... |
Apr 19, 2007 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Jan 3, 2007 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Nutraceutical preparations for treating and conducting medical research in the field of sickle cell disease
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005